Kornimate/medical-research-clean huggingface dataset:
orthophonic and / or proprioceptive treatment of developmental dyslexia.

Conditions: Developmental Dyslexia

Summary: to show the interest of the association of proprioceptive and orthophonic care of dyslexic children. the assumption is that proprioceptive support by correcting a centrally located spatial localization instability restores the ability to automate. it allows a gain of effectiveness of the orthophonic remediation of the reading of dyslexic children. interventional comparative study over 9 months, of three modes of care: speech-language, or proprioceptive, or combined (speech therapy or proprioceptive)


Eligibility criteria:
inclusion criteria: * developmental dyslexia, (cim-10) * having benefited from 2 years of speech therapy. * pathological reading delay of more than 24 months or -2 standard deviations. * either in the course of orthophonic care, or having stopped any orthophonic care. exclusion criteria: * refractive correction above +/- 1.5 diopters. * absence of binocular vision. * amblyopia. * convulsion.
comparison of the effect of remimazolam with sevoflurane on postanesthetic shivering

Conditions: Anesthesia; Hypothermia

Summary: the incidence of postanesthetic shivering (pas) after general anesthesia is affected by the anesthesia maintenance agents. this study compared the effect of remimazolam with sevoflurane on pas in patients with laparoscopic gynecologic surgery under general anesthesia.

inadvertent perioperative hypothermia and postanesthetic shivering (pas) are common after anesthesia regardless of anesthesia methods. the incidence of perioperative hypothermia and pas after general anesthesia has been reported to be 37.5 to 77.2% and 20 to 70%, respectively. shivering begins when vasoconstriction, a major mechanism to prevent body heat loss, is insufficient. pas is one of the most common discomforts in the recovery room after general anesthesia. therefore, pas is common in hypothermic patients. volatile or intravenous anesthetics impair the autonomic thermoregulatory vasoconstriction which usually preserves core body temperature. however, benzodiazepines, such as midazolam, do not significantly impair thermoregulation control, even when used in combination with common opioid doses. remimazolam, a novel benzodiazepine, has been reported for the thermoregulatory vasoconstriction threshold and onset time of vasoconstriction in terms of core body temperature in patients undergoing robotic-assisted and laparoscopic radical prostatectomy. it decreased the vasoconstriction threshold less than propofol, one of the intravenous anesthetics, and the onset of vasoconstriction was faster than propofol. investigators hypothesized that remimazolam reduced the incidence of hypothermia compared to sevoflurane, one of the volatile anesthetics, and eventually lowered the frequency of pas. therefore, this study compared the effect of remimazolam with sevoflurane on pas in patients with laparoscopic gynecologic surgery under general anesthesia.

Eligibility criteria:
inclusion criteria: * patients aged between 19 and 65 y, with asa physical status classes i or ii exclusion criteria: * patients with history such as thyroid disease, cardiopulmonary disease, blood coagulation disorder, liver dysfunction, cranial nerve disease, alcohol or drug abuse, a known allergy to the study drug, and those who had core body temperature \> 38°c or \ 30 kg.m-2 or febrile illness were excluded. patients who underwent surgery for less than 60 min, and those who did not consent to this study

Keywords: shivering general anesthesia laparoscopic surgery
effect of low-dose esketamine on postoperative depression in patients with breast cancer

Conditions: Depression

Summary: esketamine is an optical isomer of ketamine. compared with ketamine, esketamine has the characteristics of higher effective value, stronger receptor affinity, less adverse reactions of nervous system, and pharmacokinetics is controllable. domestic and foreign studies have focused on the therapeutic effect of esketamine on major depression, but less attention has been paid to perioperative depression.this study intends to explore the effect of small doses of esketamine on patients with breast cancer.postoperative depression and pain are observed.

this study intends to explore the effect of small doses of esketamine on patients with breast cancer.we pay attention to : 1. safety of low-dose single intravenous injection of esketamine (1)the influence of intraoperative vital signs of patients after medication, such as blood pressure and heart rate fluctuation; (2)the duration of recovery after anesthesia; (3)postoperative adverse reactions, such as nausea and vomiting, dizziness and diplopia, respiratory depression, laryngeal spasm, delirium agitation, etc 2. effect of single intravenous injection of low-dose ketamine on postoperative depression in patients undergoing radical mastectomy (1) 1 day before surgery, 2 days, 5 days, 30 days, 90 days after surgery hamilton depression scale scores; (2) the serum leptin level 1 day before surgery, 2 days after surgery and 5 days after surgery; (3) correlation between depression scale score and leptin level 3. effects of low dose esketamine on acute and chronic pain in patients undergoing radical mastectomy * visual analogue scale scores at 6, 12 and 24 hours after surgery; * visual analogue scale scores at 3, 5, 30 and 90 days after surgery; * the number of analgesic remedies

Eligibility criteria:
inclusion criteria: * (1) female patients who planned to undergo unilateral modified radical mastectomy in breast surgery; (2)years of education ≥5 years,american society of anesthesiologists ⅰ-ii grade; (3) all patients undergoing surgery within 1 week after diagnosis of breast cancer, and do not receive preoperative radiotherapy or chemotherapy; (4) all the patients were married and had children, and were mainly cared for by their immediate family members after surgery. exclusion criteria: * (1) antidepressant treatment was received within the last 2 months; (2) previous personality disorder, intellectual retardation, brain injury or brain disease, combined with schizophrenia, mania and other mental diseases; (3) preoperative patients with hyperthyroidism or hypothyroidism, severe cardiovascular disease, diabetes, severe blood deficiency, and abnormal heart, lung, liver, and kidney functions; (4) with diseases of the immune system, or use drugs that have obvious effects on the immune system; (5) pregnancy or lactation;

Keywords: esketamine depression pain leptin
systematic ipp vs symptomatic ipp in gerd prevention after poem for achalasia. . a comparative retrospective analysis

Conditions: Achalasia; Gastroesophageal Reflux

Summary: poem is a minimally invasive endoscopic therapy that is highly efficacy in the treatment of achalasia of any type. poem has an increased risk of gerd. systematic ppi therapy has never been studied for the prevention of post-poem gerd. the investigators wish to retrospectively compare patients who have received routine ppi therapy vs. patients who don't.


Eligibility criteria:
inclusion criteria: * \> 18 years old * consent given * achalasia all types with eckhardt score \> 3 exclusion criteria: * patient who is a minor or under judicial protection * pregnant or breastfeeding woman * contraindication to ppis * carrier of mediastinal and exogastric neoplasia * patient on ppis prior to the procedure for indication that does not allow for their discontinuation * peptic esophagitis (grade b, c or d) before or at the time of the procedure * previous treatment with heller myotomy

Keywords: gerd poem achalasia ppi esophagitis
fecal microbiota transplant (fmt) for relapsing c. difficile infection in adults and children using a frozen inoculum

Conditions: Clostridium Difficile Infection

Summary: fecal microbiota transplantation (fmt) is the reconstitution of normal flora by a "stool transplant" from a healthy individual to a c. difficile-infected recipient, and has long been a successful approach to recurrent/refractory c. difficile. the purpose of this project is to generate a frozen fmt inoculum from well-screened healthy volunteer donors which can be used repeatedly, particularly in those who do not have a healthy intimate partner or other related donor. delivery of fmt has been performed colonoscopically, by fecal retention enema, or by the nasogastric route. this study will evaluate the safety and secondarily the efficacy of a frozen inoculum administered by nasogastric tube vs administered by colonoscope. subjects with recurrent/relapsing c. difficile infection (10 per group) will receive fmt via either: * colonoscopy * ngt the primary endpoint is assessment of safety as measured by clinical events (gi, procedural, systemic). efficacy will be defined as a resolution of diarrhea off antibiotics for c. difficile, in the absence of a need for other systemic antibiotics, i.e. resumption of a normal bowel status for the individual. secondary efficacy endpoints include weight, subjective well-being and relative clinical improvement per standardized questionnaire, and subject qualitative assessment of, and satisfaction with, the transplant procedures. subjects will be monitored for clinical safety by history and standard exams and the follow-up questionnaire as well as followed closely by phone and in person.


Eligibility criteria:
inclusion criteria: * patients with recurrent or relapsing cdi defined as either(13): * at least three episodes of mild-to-moderate cdi and failure of a 6-8 week taper with vancomycin with or without an alternative antibiotic (e.g. rifaximin, nitazoxanide). * at least two episodes of severe cdi resulting in hospitalization and associated with significant morbidity. * willingness to accept risk of unrelated donor stool * willingness to be randomized to ngt vs. colonoscopic delivery. * able to consent for self, or parental assent/child assent as age appropriate. exclusion criteria: * anatomic contraindication to ngt * delayed gastric emptying syndrome * known chronic aspiration * contraindication to colonoscopy (asa 4 or more) * high risk of bacterial translocation (immunosuppression, cirrhosis etc) * pregnant or breastfeeding women * acute unrelated infection or comorbid illness exaccerbation

Keywords: fecal microbiota transplant clostridium difficile diarrhea
bepact- lung: impact of patient characteristics on pneumo-oncologists non small cell lung cancer (nsclc) systemic treatment decision in belgium

Conditions: Stage IV Non-small Cell Lung Cancer

Summary: the treatment landscape of metastatic non small cell lung cancer (nsclc) is rapidly evolving. there are new diagnostic and treatment options available in the coming months and years. new combination treatments will give different solutions to pneumo-oncologists who might be guided by certain patient and tumor characteristics. the link between patient and tumor characteristics in untreated stage iv non small cell lung cancer (nsclc) patients and systemic treatment needs further investigation, allowing the identification of possible treatment issues, data gaps and/or areas of improvement.

this is a multicenter, non-interventional, cross-sectional study. consecutive patients with metastatic stage iv non small cell lung cancer (nsclc) selected for systemic treatment or best supportive care will be included in the trial at the time the patient signed the informed consent form (icf). patients that were selected for systemic treatment, should have received at least their first dose and a maximum of one cycle of the same treatment. the pneumo-oncologist that treats the patient will fill in the crf, indicating the systemic treatment option and the link with the variable categories that impacted the choice for a systemic treatment option.

Eligibility criteria:
inclusion criteria: * have voluntarily agreed to participate by giving written informed consent/assent for the trial. * have a histologically or cytologically confirmed diagnosis of stage iv non-small cell lung cancer (nsclc) on first-line (1l) systemic treatment. * have received at least their first dose of the selected systemic treatment and a maximum of 1 cycle of the same treatment. patients that were selected to receive best supportive care will not have to comply to this inclusion criterion. * be ≥ 18 years of age on day of signing informed consent. exclusion criteria: * has received prior systemic treatment for their metastatic non-small cell lung cancer (nsclc) before the first dose of trial treatment. however, subjects who received adjuvant or neoadjuvant therapy during an earlier stage of their disease, but evolved to stage iv, are eligible. * tyrosine kinase inhibitor (tki) selected as first-line systemic treatment. * is participating in an interventional trial or medical need program.

Keywords: treatment choice
study of cellutome system for treatment of individual lesions in eb pts

Conditions: Epidermolysis Bullosa

Summary: few but persistent wounds often remain even after successful hematopoietic cell transplantation for systemic genodermatosis epidermolysis bullosa (eb). the investigators propose local wound therapy using epidermal skin grafting from the same donor that provided the hematopoietic graft, or from the same eb individual with a mosaic (naturally gene corrected) skin. in both cases permissive immune system and skin chimerism is expected to enable long-term epidermal engraftment and wound healing. the investigators will use fda approved vacuum device (cellutome®, regulation number 878.4820) that enables scar-free harvesting of epidermis and its transfer on a non-adherent silicone dressing (adaptic) to the recipient as a wound dressing.


Eligibility criteria:
inclusion criteria: patient (recipient) * diagnosis of dystrophic epidermolysis bullosa (deb) or junctional epidermolysis bullosa (jeb) with at least one wound, visibly free from infection (or previously treated) and meets the eligibility for arm a or arm b based on the skin graft source: * cell harvest from previous hematopoietic cell transplantation (hct) donor (arm a) - not applicable if arm b * at least 6 months after hematopoietic cell transplantation with donor chimerism * peripheral blood donor chimerism should be measured within 21 days of grafting and be \>/= 5% and stable. stability of chimerism will be determined by the protocol team and based on 3 peripheral blood chimerism values at least 1 month apart. * no history of pre-bmt autoimmune cytopenias * off immune suppressive therapy * original transplant donor is available and willing to be the epidermis donor * self-donation (arm b) - not applicable if arm a * proven somatic reversion * site for skin grafting free of cellulitis and any other clinically evident abnormalities * meets donor eligibility * insurance pre-authorization for procedure, if applicable * voluntary written consent (patient or parent/guardian for minors with assent) prior to any research related procedures or treatment. skin graft donor (either hematopoietic cell transplantation donor for the eb patient \[arm a\] or eb patient herself/himself \[arm b\]) * age \> 2 years (based on prior safety testing of the device) * healthy on physical examination in the opinion of the evaluating provider * negativity for hepatitis b and c, hiv, and htlv1/2 within 30 days of donation * voluntary written consent (donor or parent/guardian for minors with assent) prior to any research related procedures
study of eye movements (eye) as early markers of brain dysfunction (brain) in parkinson's disease (park)

Conditions: Parkinson Disease

Summary: identify the neural bases of eye movements during visual tasks and their dysfunction at early stages of parkinson disease (de novo).


Eligibility criteria:
inclusion criteria for all: * visual acuity normal or corrected to normal * affiliation to a social security scheme (copy of the vital card in support) * signed informed consent * medical examination according to the participation in the mri examination * mmse score\> 23/30 for parkinson patient: * diagnosis of parkinson's disease * presence of asymmetric bradykinesia and rest tremor and / or stiffness * hoehn \& yahr stadium i-ii / v exclusion criteria for all: * unprotected majors unable to express their consent * protected major (persons mentioned in articles l1121-5,6 and 8 of the public health code) * significant hearing or motor impairment * past or present neuropsychiatric pathology (except benign epilepsy) * taking narcotics and / or drugs for neurocognitive purposes * existence of a severe condition in general (cardiac, respiratory, hematological, renal, hepatic, cancerous) * any other neurodegenerative pathology or treatment that may affect the oculomotor control for parkinson patient: * treatment for parkinson's disease (except the inhibitors of monoaminoxidase b or mao-b, such as selegiline and rasagiline).
study to compare efficacy and safety of primapur and gonal-f in women for assisted reproductive treatment

Conditions: Infertility, Female

Summary: the purpose of this study is to show equivalence with regard to the number of oocytes retrieved between follitropin alfa (pen-injectors) primapur® and gonal-f® in woman undergoing ivf/icsi


Eligibility criteria:
inclusion criteria: * infertility due to tubal factor and/or male factor * age between 20 and 35 years with regular menstrual cycles of 21-35 days * first or second cycle in the present series of art * bmi (body mass index) ≥ 18 ≤ 30 kg/m2 * basal fsh (follicle stimulating hormone) \< 10 iu/l (cycle day 2-5) * e2 (estradiol) levels \< 50pg/ml (cycle day 2) * amh (anti-mullerian hormone) ≥ 1.0 ng/ml * antral follicle ≥ 4 to ≤ 15 follicles (both ovaries) * presence of both ovaries and normal uterine cavity * informed consent exclusion criteria: * presence of pregnancy * hypersensitivity to follitropin alfa * ovarian cysts * history of ≥2 succeeding art (assisted reproductive technology) cycles ivf (in vitro fertilization) and/or icsi (intracytoplasmic sperm injection) before the study cycle * previous history of severe ovarian hyperstimulation syndrome * presence of polycystic ovaries (pco) * presence of endometriosis and hydrosalpinx * presence of uterine disorders * history of poor (\ 25 oocytes) responses to fsh treatment at dose 150 iu and gnrh-antagonist (gonadotropin-releasing hormone) protocol * premature ovarian failure * ectopic pregnancy (3 month before the study cycle) * presence of clinically significant systemic disease * presence of chronic cardiovascular, hepatic, renal or pulmonary disease * presence of endocrine disorder * neoplasia * male infertility without mobile spermatozoa in the ejaculate, that need mesa (microsurgical epididymal sperm aspiration)/tese (testicular sperm extraction)/tesa (testicular sperm aspiration) * smoking \> 10 cigarettes/day * narcomania, alcoholism * planned pgs (preimplantation genetic screeneing) /pgd (preimplantation genetic diagnosis)

Keywords: in vitro fertilization
hstnt in patients admitted to the ed with atrial fibrillation in the era of noacs - heidelberg registry of atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the purpose of the heidelberg registry of atrial fibrillation (hera-fib) is to collect data on the prevalence and clinical significance of elevated cardiac troponin in a large registry of unselected patients with atrial fibrillation presenting to an emergency department in the era of novel oral anticoagulants (noacs).


Eligibility criteria:
inclusion criteria: * documented atrial fibrillation * availability of at least one hstnt measurement exclusion criteria: * none
an open-label, long-term study of oral treprostinil in subjects with pulmonary arterial hypertension

Conditions: Pulmonary Arterial Hypertension

Summary: this study is an international, multi-center, open-label study designed to provide oral treprostinil (ut-15c) to eligible subjects with pulmonary arterial hypertension who have completed the tde-ph-310 study. the purpose of this study is to assess the long-term safety of ut-15c and to assess the effects of long-term treatment with ut-15c on exercise capacity.


Eligibility criteria:
inclusion criteria: * participated in united therapeutics study tde-ph-310 * all women of childbearing potential (wocbp) must have practiced true abstinence from intercourse when it was in line with their preferred and usual lifestyle or used 2 different forms of highly effective contraception for the duration of the study and for at least 30 days after discontinuing study medication. * males who participated in the study must have used a condom during the length of the study and for at least 48 hours after their last dose of study medication. exclusion criteria: * the subject was pregnant or lactating. * the subject had received infused or inhaled prostacyclin therapy for 29 days or more. * the subject was prematurely discontinued from tde-ph-310 for reasons other than a clinical worsening event. * the subject developed a concurrent illness or condition during the conduct of tde-ph-310 which, in the opinion of the investigator, would represent a risk to their overall health if they enrolled in this study.

Keywords: pah ph freedom 6 minute walk test treprostinil open label
regional-anaesthesiological infiltration techniques for the management of chronic pain: a retrospective study

Conditions: Chronic Pain; Trigeminal Neuralgia; Cluster Headache; Post-Zoster Neuralgia; Post Zoster Pain; Neuropathic Pain

Summary: there is a significant debate whether local infiltration techniques may be a method to treat complicated chronic pain syndromes, e.g. refractory headache. until now there is a lack of evidence regarding efficacy of this treatment especially in long term follow up. similarly, indication and management are under debate. aim of this trial is to analyse pain scores during first treatment with anaesthesiological infiltration series.


Eligibility criteria:
inclusion criteria: * patients with chronic pain disease undergoing regional-anaesthesiological infiltration series exclusion criteria: * pregnancy * patients in legal custody * age \<18 years

Keywords: regional-anaesthesiological infiltration block series invasive pain treatment
post-marketing surveillance of berodual® metered-dose inhaler in the treatment of chronic obstructive respiratory tract disease

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the aim of this post-marketing surveillance is to obtain further information about the tolerability of berodual® metered-dose inhaler in the treatment of chronic obstructive respiratory tract disease under conditions of daily practice


Eligibility criteria:
inclusion criteria: * patients with diagnosis of chronic obstructive respiratory tract disease * patients of either sex, including children over 6 years exclusion criteria: - contraindications listed in the instructions of use/summary of product characteristics of berodual® metered-dose inhaler